---
title: "Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report. Covers Cost-effectiveness evidence. 24 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics/cost-effectiveness"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: published economic evaluations

No cost-effectiveness analysis, budget impact model, or health technology assessment of obefazimod was identified as of November 2026, and no obefazimod price has been announced. Published U.S. evaluations address the advanced therapies obefazimod would join. The Institute for Clinical and Economic Review (ICER) 2020 review modeled six targeted immune modulators and two biosimilars in moderate-to-severe ulcerative colitis with a Markov model of eight-week cycles, a health care sector perspective, a lifetime horizon, and 3% annual discounting. Cost per QALY ranged from $186,000 (infliximab-dyyb) to $1,870,000 (adalimumab); in the biologic-experienced population, the incremental cost-effectiveness ratio against conventional treatment ranged from $495,000 (tofacitinib) to $1,885,000 (adalimumab). ICER's five-year potential budget impact analysis of ustekinumab estimated that about 21% of eligible patients could be treated at wholesale acquisition cost, and about 51% at estimated net price, without crossing its threshold of approximately $819 million per year.

Bloudek et al. evaluated 21 treatment sequences in the base case and found infliximab or a biosimilar first line optimal by net health benefit and cost minimization. ICER's 2026 special assessment of Entyvio for the Centers for Medicare & Medicaid Services (CMS) used a lifetime Medicare model and found 30-day price premiums for Entyvio over infliximab in ulcerative colitis of $420 to $550 across thresholds of $50,000 to $200,000 per evLY, and no price premium supported over ustekinumab. Gulati et al. estimated cost per remission for mirikizumab and ustekinumab as second-line therapy from a U.S. commercial payer perspective. Shaffer et al. found that continuing 5-aminosalicylate with a biologic or tofacitinib was dominated by monotherapy. A review of 40 cost and health care resource use studies by Cichewicz et al. reported that biologic costs were not always offset by lower disease management costs and that switching and dose escalation increased drug costs. Each of these models is a candidate structure for a plan's obefazimod evaluation, and each would need an obefazimod price, which does not yet exist, and comparative efficacy inputs.

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [Pandey et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391273/); [Bloudek et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390993/); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [Gulati et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40351121/); [Shaffer et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8075066/); [Cichewicz et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130125/)

<a id="topic-4.1-2"></a>

#### Summary: inputs available and absence of an obefazimod price or model

No budget impact model of obefazimod was identified, and Abivax has published no price. A plan building its own model can draw the eligible population from the U.S. prevalence of ulcerative colitis, 378 per 100,000, or 0.64% of Medicare fee-for-service beneficiaries. No recent peer-reviewed estimate of the moderately to severely active share exists; ICER's 2020 model used 22%, from the Crohn's and Colitis Foundation. Advanced-therapy uptake among patients newly diagnosed with ulcerative colitis in 2019 to 2023 was 27% at 1 year and 38% at 5 years. Abivax estimates about 271,000 U.S. advanced-therapy patients in 2025 and about 300,000 moderate-to-severe patients on conventional therapy or steroids only, and its research names that conventional-therapy group as the population in which physicians would likely start obefazimod.

The obefazimod price figures available are analyst assumptions: LifeSci Capital assumed a U.S. net annual price at launch of US$78,000, increased from US$66,000. Comparator costs available from public sources include ICER's January 2026 Medicare inputs (annual maintenance net cost $39,423 for intravenous vedolizumab, $27,221 for subcutaneous ustekinumab biosimilar, and $5,430 for an intravenous infliximab biosimilar in ulcerative colitis), the Medicare negotiated price for Stelara of $4,695.00 per 30-day supply, and wholesale acquisition costs reported to California for tofacitinib, upadacitinib, ozanimod, etrasimod, risankizumab, mirikizumab, and vedolizumab. Medicare negotiated prices for Entyvio and Xeljanz, selected for negotiation, take effect beginning in 2028. Non-drug inputs (colectomy $33,871 per admission; health-state costs) come from ICER's 2020 model. These inputs differ in date, price basis (list, net, or negotiated), and payer, so a plan would need to align them before use.

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook); [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html); [CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024)](https://cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf); [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27SKYRIZI%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Xeljanz%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Entyvio%25%27); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%2246b78eef-5952-4fff-84c7-1fa758990ce8%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27RINVOQ%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27ZEPOSIA%25%27); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%20FROM%20%22f0899438-0fb5-42d5-87f5-621e2f0b1b51%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27VELSIPITY%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27OMVOH%25%27)

<a id="topic-4.1-3"></a>

#### Targeted immune modulators versus conventional treatment: ICER U.S. cost-effectiveness model, 2020

> “The model was structured as a Markov model with eight-week cycles consisting of the health states of active UC, clinical response without remission, clinical remission, post-colectomy (with and without complications), and death.”
> “The base-case analysis took a health care sector perspective (i.e., focused on direct medical care costs only), over a lifetime time horizon. Costs and outcomes were discounted at 3% per year.”
> “ranged from $186,000 (infliximab-dyyb) to $1,870,000 (adalimumab)”
> “None of the TIMs were cost effective compared to infliximab.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-4.1-4"></a>

#### Targeted immune modulators versus conventional treatment: peer-reviewed summary of the ICER 2020 model

> “We evaluated the cost-effectiveness from the U.S. health care sector perspective of the 6 TIMs and 2 biosimilars over a lifetime time horizon.”
> “The average net pricing estimates for TIMs with oral and subcutaneous modes of administration were obtained from SSR Health. For IV-administered TIMs, we used Centers for Medicare & Medicaid Services average sales prices (ASP) plus 9.5%.”
> “cost-effectiveness was closest to $150,000 per quality-adjusted life-year (QALY) for infliximab and its biosimilars: infliximab-dyyb and infliximab-adba ($212,000, $186,000 and $195,000 per QALY, respectively).”
> “In the biologic-experienced population (Table 2), the incremental cost-effectiveness ratio compared with conventional treatment was highest for adalimumab ($1,885,000) and lowest for tofacitinib ($495,000).”
> “The primary limitations of our cost-effectiveness analysis included restricted data availability, a paucity of information on treatment sequencing or switching, and our need to base outcomes for conventional treatment solely on the results from the placebo arms of the trials.”

Source: [Pandey et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391273/)

<a id="topic-4.1-5"></a>

#### Ustekinumab: ICER U.S. potential budget impact analysis, 2020

> “We used the cost-effectiveness model to estimate the potential total budgetary impact of the recently expanded indication of ustekinumab for prevalent individuals in the US”
> “Potential budget impact was defined as the total differential cost of using this new therapy rather than relevant existing therapies for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events.”
> “All costs were undiscounted and estimated over a five-year time horizon, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.”
> “the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $819 million per year for new drugs.”
> “approximately 21% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million at the WAC of ustekinumab. Approximately 51% of eligible patients could be treated without crossing the budget impact threshold at its estimated net price.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

| Annualized per-patient budget impact over five years | At list price | At net price | At $150,000/QALY price | At $100,000/QALY price | At $50,000/QALY price |
| --- | --- | --- | --- | --- | --- |
| Ustekinumab | “$73,600” | “$53,100” | “$28,800” | “$27,600” | “$26,400” |
| Market basket (55% biologic-naive, 45% biologic-experienced) | “$37,500” | “$37,500” | “$37,500” | “$37,500” | “$37,500” |
| Net impact | “$36,100” | “$15,600” | “-$8,700” | “-$9,900” | “-$11,100” |

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-4.1-6"></a>

#### Treatment sequences of targeted immune modulators: U.S. payer cost-effectiveness model

> “The model was developed as a Markov model with 8-week cycles over a lifetime time horizon from a US payer perspective, including only direct health care costs.”
> “Drug costs were updated to reflect prices as of May 2020.”
> “21 possible sequences were evaluated in the base case.”
> “None of the sequences had an incremental cost per QALY below $150,000 relative to 2 attempts with conventional treatment, so the resulting NHB was negative for all sequences.”
> “Based on the results of this analysis, the optimal sequence of TIMs as measured by NHB and cost minimization was infliximab or biosimilars as first-line treatment, then moving to tofacitinib, adalimumab, or vedolizumab. Sequences that generated the most QALYs began with ustekinumab, followed by vedolizumab, tofacitinib, and adalimumab.”

Source: [Bloudek et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390993/)

<a id="topic-4.1-7"></a>

#### Vedolizumab versus infliximab and ustekinumab: ICER special assessment for Medicare price negotiation, 2026

> “We used decision-analytic modeling to assess the lifetime projected effectiveness and cost of Entyvio compared to infliximab and ustekinumab for UC and CD.”
> “Costs and outcomes were discounted at 3% per year. Both models focused on a hypothetical cohort of Medicare patients with moderately to severely active UC or CD who initiated treatment with Entyvio, infliximab, or ustekinumab.”
> “Compared to infliximab in UC, 30-day price premiums relative to the cost to CMS of infliximab were $420 at $50,000/evLY, $460 at $100,000/evLY, $510 at $150,000/evLY, and $550 at $200,000/evLY.”
> “Compared to ustekinumab, Entyvio was not associated with health gains in UC or CD, and therefore decision analytic modeling confirmed that the evidence does not support a price premium for Entyvio above CMS pricing for ustekinumab.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-4.1-8"></a>

#### Mirikizumab versus ustekinumab after biologic or Janus kinase inhibitor exposure: U.S. commercial payer cost per remission model

> “An Excel-based analytic model was developed to estimate the cost per additional patient achieving clinical remission at the end of one year in biologic/Janus kinase inhibitor (JAKi)-experienced patients (second-line therapy) with UC from a United States commercial payer perspective.”
> “The model included the treatment cost (wholesale acquisition costs [WAC] and treatment administration costs) during the induction and maintenance phases.”
> “The costs per patient achieving clinical remission for mirikizumab vs. ustekinumab as a second-line therapy were $461,096 vs. $67,273 during induction and $501,456 vs. $1,079,189 during maintenance.”
> “Considering the ustekinumab 130 mg IV biosimilar, the scenario resulted in a lower cost per clinical remission for mirikizumab vs. a ustekinumab biosimilar during the maintenance phase ($501,456 vs. $539,594).”

Source: [Gulati et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40351121/)

<a id="topic-4.1-9"></a>

#### Continuing versus stopping 5-aminosalicylate with a biologic or tofacitinib: U.S. cost-effectiveness model

> “Medications are major cost drivers in the treatment of patients with inflammatory bowel disease.”
> “Our model shows that biologic/tofacitinib monotherapy dominates (cheaper and more effective) combination therapy of biologics/tofacitinib with 5-ASA. Probabilistic sensitivity analyses simulations resulted in biologic/tofacitinib monotherapy dominating 100% of the scenarios, with mean cost savings of $24,483.01 over 2 years.”

Source: [Shaffer et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8075066/)

<a id="topic-4.1-10"></a>

#### Costs of advanced therapies in moderate-to-severe ulcerative colitis: systematic review of observational studies

> “47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included.”
> “High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes.”

Source: [Cichewicz et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130125/)

<a id="topic-4.1-11"></a>

#### Prevalence of ulcerative colitis in the United States, pooled commercial, Medicare, and Medicaid claims

> “The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.”
> “Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.”

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-4.1-12"></a>

#### Prevalence of ulcerative colitis among Medicare fee-for-service beneficiaries

> “Among 25 million Medicare fee-for-service beneficiaries, there are approximately 100,000 people with CD (0.40%) and 160,000 people with UC (0.64%).”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-4.1-13"></a>

#### Share with moderate-to-severe disease activity: ICER 2020 eligible-population estimate

> “we used an estimate by Turner et al. of the prevalence of individuals with UC in the US of approximately 900,000 patients.”
> “The Crohn’s and Colitis Foundation has reported that approximately 22% of UC patients have moderate-to-severe disease activity in a given year, which would equate to approximately 198,000 patients”
> “we assumed a fixed ratio of 55% biologic-naïve and 45% biologic-experienced patients”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-4.1-14"></a>

#### Uptake of advanced therapy after diagnosis among commercially insured U.S. adults

> “Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-4.1-15"></a>

#### Company estimates of U.S. advanced-therapy use and of moderate-to-severe patients on conventional therapy

> “From 2020 to 2025, U.S. advanced therapy usage has increased by approximately 96% from approximately 138,000 advanced therapy patients in 2020 to approximately 271,000 advanced therapy patients in 2025.”
> “We currently estimate that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment.”
> “In the United States, UC sales were approximately $6.0 billion in 2025 and are expected to reach $14.9 billion by 2032.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “The research estimated that roughly 500K patients within the United States are currently on conventional therapies (5ASA’s/corticosteroids), with approximately 60% of these patients being moderate/severe (~300K patients). Physicians indicated they would likely initiate treatment with obefazimod for this population where reluctance to advanced therapies hinder their use.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-4.1-16"></a>

#### Analyst assumption: LifeSci Capital U.S. net annual price at launch, June 2026

> “On June 30, Sam Slutsky and Kate Dellorusso, Ph.D., of LifeSci Capital gave Abivax an outperform rating, with a target price of US$170.”
> “Our assumptions are as follows: obefazimod enters the market for moderate to severe ulcerative colitis in 2027, reaching 2039 global peak sales of US$4.2 nillion (risk-adjusted sales of US$3.8 billion). We currently assume a 90% probability of success with a net annual price at launch of US$78,000 in the U.S. (increased from US$66,000 prior based on recent management commentary)”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-4.1-17"></a>

#### Comparator drug costs in the ICER Medicare model, prices of January 2026

> “Drug costs for the model are outlined in Table E2.20 based on January 21, 2026 price estimates.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

| Drug | WAC per dose | Discount from WAC | Primary source | Net price per dose | Annual net cost of maintenance |
| --- | --- | --- | --- | --- | --- |
| Vedolizumab IV (Entyvio) | “Not Applicable” | “Not Applicable” | “ASP” | “$6,048” | “$39,423” |
| Vedolizumab SC (Entyvio) | “$3,639” | “29.23%” | “REDBOOK” | “$2,575” | “$67,145” |
| Infliximab IV (biosimilar) | “Not Applicable” | “Not Applicable” | “ASP” | “$833 (UC)” | “$5,430 (UC)” |
| Infliximab SC (Zymfentra) | “$3,343” | “10%” | “REDBOOK” | “$3,008” | “$78,435” |
| Ustekinumab IV (biosimilar), induction only | “Not Applicable” | “Not Applicable” | “ASP” | “$3,522” | Not applicable |
| Ustekinumab SC (biosimilar) (90 mg) | “$4,176” | “Not Applicable” | “REDBOOK” | “$4,176” | “$27,221” |

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

> “†Weight-based dosing assuming 73.4 kg for UC and 70.0 kg for CD.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-4.1-18"></a>

#### Ustekinumab: Medicare negotiated price effective January 2026 and 2023 list price

| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2026 | List price for 30-day supply, CY 2023 | Discount of negotiated price from 2023 list price |
| --- | --- | --- | --- | --- |
| Stelara (ustekinumab) | “Janssen Biotech, Inc.” | “$4,695.00” | “$13,836.00” | “66%” |

Source: [CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024)](https://cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf)

> “List prices are rounded to the nearest dollar and represent the Wholesale Acquisition Costs (WACs) for the selected drugs based on 30-day supply using CY 2022 prescription fills.”

Source: [CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024)](https://cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf)

<a id="topic-4.1-19"></a>

#### Vedolizumab and tofacitinib: selection for the third cycle of Medicare price negotiation

> “Any negotiated prices will be effective beginning in 2028.”

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

| Selected drug | Drug name | Participating manufacturer |
| --- | --- | --- |
| Vedolizumab | “Entyvio” | “Takeda Pharmaceuticals U.S.A., Inc.” |
| Tofacitinib | “Xeljanz; Xeljanz XR” | “PF PRISM CV” |

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

<a id="topic-4.1-20"></a>

#### Wholesale acquisition costs of risankizumab, tofacitinib, and vedolizumab reported to California, 2026

| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
| --- | --- | --- | --- | --- | --- |
| Skyrizi (risankizumab) 600 mg vial | “AbbVie” | “SKYRIZI VIAL (ML) 600 mg/10 mL (60 mg/mL) 10” | “2026-07-01T00:00:00” | “272.45” | “11170.27” |
| Skyrizi (risankizumab) 180 mg on-body injector | “AbbVie” | “SKYRIZI ON-BODY WEARABLE INJECTOR 180 mg/1.2 mL (150 mg/mL) 1.2” | “2026-01-02T00:00:00” | “1454.93” | “23838.42” |
| Skyrizi (risankizumab) 360 mg on-body injector | “AbbVie” | “SKYRIZI ON-BODY WEARABLE INJECTOR 360 mg/2.4 mL (150 mg/mL) 2.4” | “2026-01-02T00:00:00” | “1454.93” | “23838.42” |
| Xeljanz (tofacitinib) 10 mg, 60 tablets | “Pfizer” | “10 mg Tablet 60” | “2026-01-01T00:00:00” | “334.02” | “6407.16” |
| Xeljanz XR (tofacitinib) 22 mg, 30 tablets | “Pfizer” | “22mg Tablet 30” | “2026-01-01T00:00:00” | “334.02” | “6407.16” |
| Entyvio (vedolizumab) 300 mg vial | “Takeda Pharmaceuticals America, Inc.” | “Entyvio INJECTABLE 300 MG / 20 mL Vial” | “2026-01-01T00:00:00” | “748.79” | “10108.70” |
| Entyvio (vedolizumab) 108 mg pen | “Takeda Pharmaceuticals America, Inc.” | “Entyvio Pen SOLUTION PEN-INJECTOR 108 ML” | “2026-01-01T00:00:00” | “269.57” | “3639.14” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27SKYRIZI%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Xeljanz%25%27%20OR%20%22drug_prod_desc%22%20LIKE%20%27Entyvio%25%27)

<a id="topic-4.1-21"></a>

#### Wholesale acquisition costs of upadacitinib and ozanimod reported to California, January 2025

| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
| --- | --- | --- | --- | --- | --- |
| Rinvoq (upadacitinib) 15 mg, 30 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 15 mg 30” | “01/02/2025” | “321.56” | “6752.77” |
| Rinvoq (upadacitinib) 30 mg, 30 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 30 mg 30” | “01/02/2025” | “321.56” | “6752.77” |
| Rinvoq (upadacitinib) 45 mg, 28 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 45 mg 28” | “01/02/2025” | “600.24” | “12605.04” |
| Zeposia (ozanimod) 0.92 mg, 30 capsules | “Bristol Myers Squibb” | “0.92MG CAP 30CT BTL US” | “01/01/2025” | “400.04” | “9289.90” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22WAC%20Effective%20Date%22%2C%22WAC%20Increase%20Amount%22%2C%22WAC%20After%20Increase%22%20FROM%20%2246b78eef-5952-4fff-84c7-1fa758990ce8%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27RINVOQ%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27ZEPOSIA%25%27)

<a id="topic-4.1-22"></a>

#### Wholesale acquisition costs of etrasimod and mirikizumab at introduction, October 2023

| Product and package | Manufacturer | Drug product description | Date introduced to market | WAC at introduction (USD) |
| --- | --- | --- | --- | --- |
| Velsipity (etrasimod) 2 mg, 30 tablets | “Pfizer” | “VELSIPITY 2MG TFC 1X30 PBTL US” | “2023-10-19” | “6164.3800” |
| Omvoh (mirikizumab) 300 mg vial | “Eli Lilly and Company” | “OMVOH 20 mg/mL (300 mg/15 mL) 1 300 mg vial” | “2023-10-27” | “9593.2200” |
| Omvoh (mirikizumab) 100 mg/mL, 2 prefilled pens | “Eli Lilly and Company” | “OMVOH 100 mg/mL 2 single patient-use prefilled pens” | “2023-10-27” | “10360.6700” |

Source: [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%20FROM%20%22f0899438-0fb5-42d5-87f5-621e2f0b1b51%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27VELSIPITY%25%27%20OR%20%22Drug%20Product%20Description%22%20LIKE%20%27OMVOH%25%27)

<a id="topic-4.1-23"></a>

#### Annual wholesale acquisition costs and estimated net prices in the ICER 2020 model, May 2020

| Drug | Annual WAC | Annual estimated net price |
| --- | --- | --- |
| Adalimumab | “$72,400” | “$46,900” |
| Golimumab | “$75,300” | “$42,300” |
| Infliximab | “$27,900” | “$14,600” |
| Infliximab-dyyb | “$22,600” | “$13,500” |
| Infliximab-abda | “$18,000” | “$13,900” |
| Ustekinumab | “$150,400” | “$91,600” |
| Vedolizumab | “$43,800” | “$44,200” |
| Tofacitinib | “$57,200” | “$35,500” |

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

> “Finally, we applied this average discount to the most recent available WAC (May 6, 2020) to arrive at an estimated net price per dose.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-4.1-24"></a>

#### Colectomy, serious infection, and health-state costs in the ICER 2020 model

> “A cost of $33,871 per admission for colectomy is assumed, calculated by the weighted average cost of emergent and non-emergent cost per admission from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database”
> “Serious infection events are assigned a cost of $10,238 based on HCUP net mean hospital costs for an inpatient stay with ICD-10 diagnosis of pneumonia (J12-J18)”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

| Health state (annual cost, 2019 US dollars) | Hospitalization | Emergency department | Outpatient or other |
| --- | --- | --- | --- |
| Active UC | “$8,048” | “$581” | “$10,114” |
| Clinical response without remission | “$4,461” | “$410” | “$7,506” |
| Clinical remission | “$969” | “$223” | “$2,722” |

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
